



(51) International Patent Classification:

C07K 16/10 (2006.01) A61P 31/12 (2006.01)
A61K 39/42 (2006.01)

(21) International Application Number:

PCT/SG2019/050145

(22) International Filing Date:

15 March 2019 (15.03.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10201802164Y 15 March 2018 (15.03.2018) SG

(71) Applicants: CHUGAI SEIYAKU KABUSHIKI

KAISHA [JP/JP]; 5-1, Ukima 5-chome, Kita-ku, Tokyo,
115-8543 (JP). AGENCY FOR SCIENCE, TECHNOL-
OGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way,
#20-10 Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: FINK, Katja; c/o Singapore Immunology Net-

work, 8A Biomedical Grove, #03-00, Singapore 138648
(SG). WANG, Cheng-I; c/o Singapore Immunology Net-


work, 8A Biomedical Grove, Level 4, Immunos Building,
Singapore 138648 (SG). NG, Lisa Fong Poh; c/o Singapore
Immunology Network, 8A Biomedical Grove, Singapore
138648 (SG). RENIA, Laurent; c/o Singapore Immunol-
ogy Network, 8A Biomedical Grove, Level 4, Immunos
Building, Singapore 138648 (SG). SAMPEI, Zenjiro; c/
o Fuji Gotemba Research Laboratories, 1-135 Komaka-
do, Shizuoka Pref., Gotemba City, 412-8513 (JP). KOO,
Xing'er Christine; c/o Chugai Pharmabody Research Pte
Ltd, 3, Biopolis Drive, #07-11 to 16 Synapse, Singapore
138623 (SG).

(74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD;
P.O. Box 1531, Robinson Road Post Office, Singapore
903031 (SG).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: ANTI-DENGUE VIRUS ANTIBODIES HAVING CROSS-REACTIVITY TO ZIKA VIRUS AND METHODS OF USE

Figure 19



(57) Abstract: The disclosure provides anti-dengue virus (anti-DENV) antibodies having a cross-reactivity to Zika virus (ZIKV) and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection. In addition, claimed antibodies may further comprise variant Fc regions containing LALA, KAES & ACT5 mutations.

[Continued on next page]

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*